Literature DB >> 6161872

Three rat monoclonal antibodies to human C3.

P J Lachmann, R G Oldroyd, C Milstein, B W Wright.   

Abstract

Three monoclonal antibodies to human C3 have been obtained from a fusion of the rat myeloma line Y3 Ag 1.2.3. with spleen cells from rats immunized against C3. One, from clone 4, reacts with an antigenic determinant in C3c showing the expected reactivity of the 'C' antigen of C3. The specificity of the other two monoclonal antibodies correspond less clearly with known C3 antigens. By agglutination analysis of complement coated cells the determinant reacting with clone 3 is present in C3d while that for clone 9 appears as a neoantigen on C3bi. In both cases the co-precipitation results are anomalous and more direct studies are needed to define the exact specificity. The possibility that internal sequence duplications in C3 may explain some anomalies is discussed. None of the monoclonal antibodies significantly inhibit C3 functions. The monoclonal antibodies have been found to have unusual properties in co-precipitation assays being able to diffuse through a precipitation line with which they react to react with a further line. One antibody is also able to react strongly with the anodal half of what appears as a single line with a polyclonal antiserum.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6161872      PMCID: PMC1458128     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  12 in total

Review 1.  Complement.

Authors:  H J Müller-Eberhard
Journal:  Annu Rev Biochem       Date:  1975       Impact factor: 23.643

2.  Continuous cultures of fused cells secreting antibody of predefined specificity.

Authors:  G Köhler; C Milstein
Journal:  Nature       Date:  1975-08-07       Impact factor: 49.962

3.  Antigenic determinants of human beta-1c and beta-1g-globulins.

Authors:  C West; N C Davis; J Forristal; J Herbst; R Spitzer
Journal:  J Immunol       Date:  1966-04       Impact factor: 5.422

4.  Anti-C3a, anti-C3B (anti-B) and their reaction with the anaphylatoxic fragment C3a.

Authors:  J L Molenaar; A ten Velde; K W Pondman
Journal:  J Immunol       Date:  1973-03       Impact factor: 5.422

5.  The demonstration in human serum of "conglutinogen-activating factor" and its effect on the third component of complement.

Authors:  P J Lachmann; H J Müller-Eberhard
Journal:  J Immunol       Date:  1968-04       Impact factor: 5.422

6.  The physiological breakdown of the third component of human complement.

Authors:  R A Harrison; P J Lachmann
Journal:  Mol Immunol       Date:  1980-01       Impact factor: 4.407

7.  Detection of specific hybridoma clones by replica immunoadsorption of their secreted antibodies.

Authors:  J Sharon; S L Morrison; E A Kabat
Journal:  Proc Natl Acad Sci U S A       Date:  1979-03       Impact factor: 11.205

8.  Transplantable immunoglobulin-secreting tumours in rats. I. General features of LOU-Ws1 strain rat immunocytomas and their monoclonal proteins.

Authors:  H Bazin; C Deckers; A Beckers; J F Heremans
Journal:  Int J Cancer       Date:  1972-11       Impact factor: 7.396

9.  Rat x rat hybrid myelomas and a monoclonal anti-Fd portion of mouse IgG.

Authors:  G Galfrè; C Milstein; B Wright
Journal:  Nature       Date:  1979-01-11       Impact factor: 49.962

10.  Reactive lysis: the complement-mediated lysis of unsensitized cells. II. The characterization of activated reactor as C56 and the participation of C8 and C9.

Authors:  P J Lachmann; R A Thompson
Journal:  J Exp Med       Date:  1970-04-01       Impact factor: 14.307

View more
  31 in total

1.  The culture of rat myeloma and rat hybridoma cells in a protein-free medium.

Authors:  M J Keen
Journal:  Cytotechnology       Date:  1995-10       Impact factor: 2.058

2.  A novel strategy for targeting CD4+ PPD-reactive T cells against tumour cells using PPD monoclonal antibody heteroconjugates.

Authors:  A M Montgomery; M G Wing; P J Lachmann
Journal:  Clin Exp Immunol       Date:  1990-11       Impact factor: 4.330

3.  The role of isotype and epitope specificity of monoclonal antibody mixtures in immunodiffusion reactions.

Authors:  B W Griffiths; A Godard; J A Caron; W Tostowaryk
Journal:  Immunology       Date:  1987-04       Impact factor: 7.397

Review 4.  Anti-GD2 antibody therapy for GD2-expressing tumors.

Authors:  Fariba Navid; Victor M Santana; Raymond C Barfield
Journal:  Curr Cancer Drug Targets       Date:  2010-03       Impact factor: 3.428

5.  Serum sickness and acute renal failure after streptokinase therapy for myocardial infarction.

Authors:  K A Davies; P Mathieson; C G Winearls; A J Rees; M J Walport
Journal:  Clin Exp Immunol       Date:  1990-04       Impact factor: 4.330

6.  Characterization of three monoclonal antibodies against C3 with selective specificities.

Authors:  K Iida; K Mitomo; T Fujita; N Tamura
Journal:  Immunology       Date:  1987-11       Impact factor: 7.397

7.  Analysis of the interactions between properdin, the third component of complement (C3), and its physiological activation products.

Authors:  T C Farries; P J Lachmann; R A Harrison
Journal:  Biochem J       Date:  1988-05-15       Impact factor: 3.857

8.  An efficient one-step method for isolating immune complexes from whole serum using a monoclonal anti-C3g affinity immunosorbent.

Authors:  D J Samuel; P L Amlot; P Shepherd; P J Lachmann
Journal:  Clin Exp Immunol       Date:  1986-08       Impact factor: 4.330

Review 9.  Monoclonal antibodies: implications for virology. Brief review.

Authors:  K C McCullough
Journal:  Arch Virol       Date:  1986       Impact factor: 2.574

10.  Monoclonal antibodies that inhibit mitogenic activity of Mycoplasma pulmonis.

Authors:  Z Lapidot; R Siman-Tov; Y Naot
Journal:  Infect Immun       Date:  1995-01       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.